Houston-based Vertex Energy Inc . (OTC Pink:OTC:VTNRQ), a petroleum refining company with annual revenues of $3.2 billion, has received confirmation from the U.S. Bankruptcy Court for the Southern ...
Animation Baker and Instancing for Animated Characters: Using GPU to implement large-amount animation characters rendering. The animation map for vertex shader to modify the vertex position of the ...
Copyright 2025 The Associated Press. All Rights Reserved. Seattle Seahawks cornerback Riq Woolen, left, shares a moment with his mother following an NFL football game ...
So BYD’s introduction of the Seal U into the UK market is timely. And the reality is that with its choice of battery and motor configurations, even if the buyer opts for the most affordable ...
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
As the marque’s lineup grew, funkier designs and oddball names appeared including the Dolphin, Sealion 7, Seal, and Seal U, the latter being the only hybrid option. The zany car that became my ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic. Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...
Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback